Chemistry and Cancer Program

化学与癌症项目

基本信息

批准号：
10693208
负责人：
Daniel John Siegwart
金额：
$ 5.22万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10693208
关键词：
Acceleration Address Antineoplastic Agents Binding Biochemical Biochemical Pathway Biochemistry Biological Biology Cancer Biology Catchment Area Chemicals Chemistry Clinic Clinical Trials Collaborations Colorectal Cancer Comprehensive Cancer Center Development Dissection Doctor of Philosophy Drug Design Foundations Funding Future Goals Human Journals Lead Leadership Licensing Malignant Neoplasms Malignant neoplasm of liver Malignant neoplasm of lung Medical Medical center Medicine Molecular Molecular Biology Molecular Target NMR Spectroscopy Oncogenes Outcome Pathogenicity Pathway interactions Patients Peer Review Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Phenotype Proteins Province Publications Reagent Regulatory Pathway Renal carcinoma Research Research Priority Resolution Role Scientist Signal Pathway Structural Biologist Structure Structure-Activity Relationship Synthesis Chemistry Techniques Translations X-Ray Crystallography biophysical techniques cancer prevention cancer therapy clinical application design drug discovery early phase trial improved insight member novel anticancer drug novel therapeutics preclinical study programs protein function small molecule structural biology synthetic lethal interaction tool translational impact translational pipeline translational study

项目摘要

The interdisciplinary Chemistry and Cancer (CC) Program is uniquely situated in Simmons Comprehensive Cancer Center (SCCC) to bridge fundamental biology research with the discovery of novel therapies for the treatment of cancer. CC has facilitated numerous intraprogrammatic and interprogrammatic collaborations, which have resulted in new insights into cancer biology and drug discovery of high clinical applicability. CC combines the expertise of synthetic and medicinal chemists, molecular and structural biologists, biochemists, chemical biologists, pharmacologists, and clinician scientists to discover, design, and optimize drug-like small molecules that regulate biological pathways deregulated in cancer. CC’s discovery platform is guided by the hypothesis that an interdisciplinary and chemically focused approach to cancer biology will provide new avenues for discovery in cancer prevention and treatment. The CC Program is co-led by Jef De Brabander, PhD, and Uttam Tambar, PhD, and is composed of 22 members who are drawn from seven departments on campus. The CC Scientific Program is defined by three specific aims: (1) Identification of Molecular Targets of Novel Anti- Cancer Agents, (2) Biochemical Dissection of Regulatory Pathways Relevant to Human Cancer, and (3) Structure-Based Design of Chemicals that Perturb Cancer-Relevant Signaling Pathways. The CC Program focuses on acceleration of the continued translation of chemical discoveries made at the UT Southwestern Medical Center (UTSW) and SCCC to the clinic, the initiation of early-stage translational studies, and the licensing of mid- to late-stage preclinical studies. The CC Program will continue to prioritize research programs that impact cancers that are prevalent in the SCCC catchment area, such as colorectal, lung, kidney, and liver cancers. In addition, the CC Program will promote interprogrammatic and intraprogrammatic collaborations and explore new projects in the three specific aims. Total direct peer-reviewed funding to the CC Program is $5.2M, with $2.6M (51%) from the NCI. CC Program members have authored 253 peer-reviewed publications since 2014, of which 17% were intraprogrammatic, 40% interprogrammatic, and 36% were in journals with impact factors ≥ 10.

跨学科化学和癌症（CC）计划独特地位于Simmons综合癌症中心（SCCC）桥接基本生物学研究，并发现了新的疗法癌症的治疗。 CC已经准备了众多的磁内图和解释合作协作，这导致了对癌症生物学的新见解，并发现了高临床适用性的药物。 CC 结合了合成和医学化学家，分子和结构生物学家，生物化学家的专业知识，化学生物学家，药品和临床科学家发现，设计和优化类似药物的小型调节生物学途径的分子在癌症中失调。 CC的发现平台由假设跨学科和化学专注的癌症生物学方法将提供新的途径用于预防癌症和治疗中的发现。 CC计划由Jef de Brabander，PhD和 Uttam Tambar，博士，由22名成员组成，这些成员来自校园的七个部门。 CC科学计划由三个特定目的定义：（1）鉴定新抗的分子靶标癌症药物，（2）与人类癌症相关的调节途径的生化清扫术，（3）基于结构的化学物质设计，这些化学物质会扰动与癌症相关的信号通路。 CC计划的重点是加速在UT上进行的化学发现的持续翻译西南医学中心（UTSW）和SCCC到诊所，早期翻译研究的倡议，以及中期至后期临床前研究的许可。 CC计划将继续优先考虑研究影响SCCC集水区普遍存在的癌症的程序，例如结直肠，肺，肾脏，和肝癌。此外，CC程序将促进概况和磁内图在三个特定目标中的合作和探索新项目。 CC计划的直接直接同行评审资金为520万美元，NCI的260万美元（51％）。 CC程序自2014年以来，成员已经撰写了253家同行评审的出版物，其中17％是磁内图， 40％的解释性截图，而36％的期刊在影响因子≥10的期刊中。